Literature DB >> 31174999

Pathophysiology, prevention, and treatment of medication overuse headache.

Hans-Christoph Diener1, David Dodick2, Stefan Evers3, Dagny Holle4, Rigmor Hoejland Jensen5, Richard B Lipton6, Frank Porreca7, Stephen Silberstein8, Todd Schwedt2.   

Abstract

Regular or frequent use of analgesics and acute antimigraine drugs can increase the frequency of headache, and induce the transition from episodic to chronic headache or medication overuse headache. The 1-year prevalence of this condition in the general population is between 1% and 2%. Medication overuse headache is more common in women and in people with comorbid depression, anxiety, and other chronic pain conditions. Treatment of medication overuse headache has three components. First, patients need education and counselling to reduce the intake of medication for acute headache attacks. Second, some patients benefit from drug withdrawal (discontinuation of the overused medication). Finally, preventive drug therapy and non-medical prevention might be necessary in patients at onset of treatment or in patients who do not respond to the first two steps. The optimal therapeutic approach requires validation in controlled trials.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31174999     DOI: 10.1016/S1474-4422(19)30146-2

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN: 1474-4422            Impact factor:   44.182


  30 in total

Review 1.  [Pain prevention in the primary care setting : Facts for resident physicians].

Authors:  C Geber; B Kappis; T Bäsch; H R Casser
Journal:  Schmerz       Date:  2021-01-06       Impact factor: 1.107

2.  Current Approach to Medication Overuse Headache.

Authors:  Elif Kocasoy Orhan
Journal:  Noro Psikiyatr Ars       Date:  2019-10-30       Impact factor: 1.339

3.  Comparison of 3 Treatment Strategies for Medication Overuse Headache: A Randomized Clinical Trial.

Authors:  Louise Ninett Carlsen; Signe Bruun Munksgaard; Mia Nielsen; Ida Maria Storm Engelstoft; Maria Lurenda Westergaard; Lars Bendtsen; Rigmor Højland Jensen
Journal:  JAMA Neurol       Date:  2020-09-01       Impact factor: 18.302

Review 4.  Tension-type headache.

Authors:  Sait Ashina; Dimos D Mitsikostas; Mi Ji Lee; Nooshin Yamani; Shuu-Jiun Wang; Roberta Messina; Håkan Ashina; Dawn C Buse; Patricia Pozo-Rosich; Rigmor H Jensen; Hans-Christoph Diener; Richard B Lipton
Journal:  Nat Rev Dis Primers       Date:  2021-03-25       Impact factor: 52.329

5.  Safety and efficacy of nimodipine combined with flunarizine in patients with angioneurotic headache.

Authors:  Tao Zhang; Yao Xiao; Shengquan Li
Journal:  Am J Transl Res       Date:  2022-01-15       Impact factor: 4.060

Review 6.  Post-traumatic Headache: Pharmacologic Management and Targeting CGRP Signaling.

Authors:  Håkan Ashina; David W Dodick
Journal:  Curr Neurol Neurosci Rep       Date:  2022-02-09       Impact factor: 5.081

Review 7.  Cluster headache pathophysiology - insights from current and emerging treatments.

Authors:  Diana Y Wei; Peter J Goadsby
Journal:  Nat Rev Neurol       Date:  2021-03-29       Impact factor: 42.937

8.  Efficacy of ubrogepant based on prior exposure and response to triptans: A post hoc analysis.

Authors:  Andrew M Blumenfeld; Peter J Goadsby; David W Dodick; Susan Hutchinson; Chengcheng Liu; Michelle Finnegan; Joel M Trugman; Armin Szegedi
Journal:  Headache       Date:  2021-03-22       Impact factor: 5.887

9.  Selective targeting of peripheral cannabinoid receptors prevents behavioral symptoms and sensitization of trigeminal neurons in mouse models of migraine and medication overuse headache.

Authors:  Toru Yamamoto; Yatendra Mulpuri; Mikhail Izraylev; Qianyi Li; Menooa Simonian; Christian Kramme; Brian L Schmidt; Herbert H Seltzman; Igor Spigelman
Journal:  Pain       Date:  2021-08-01       Impact factor: 7.926

10.  The Ruminative Thought Style with Associated Anxiety Influences the Occurrence of Medication-Overuse Headache.

Authors:  Marina Ljubisavljevic; Aleksandra Ignjatovic; Srdjan Ljubisavljevic
Journal:  J Clin Neurol       Date:  2021-07       Impact factor: 3.077

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.